Mirador Therapeutics key facts
as of Oct 2026- Developer of precision medicine technologies designed to address unmet needs in immune-mediated and inflammatory diseases.
- Mirador Therapeutics is valued at approximately $1.0B as of Oct 2026, set at its early-stage round, Jan 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $735.0M across 2 recorded rounds; the latest was Later Stage VC ($333.0M) in Feb 2024.
- Notable investors include Alexandria Venture Investments, OrbiMed, ARCH Venture Partners, Venrock, Blue Owl Capital — 17 tracked in total.
- Mirador Therapeutics has filed 2 Form Ds with the SEC, most recently Apr 2024 ($80.0M sold to 3 investors).
- Status: Privately Held (backing).
Valued at $1.0B at its early-stage round, Jan 2026. Nothing has traded since.
- ·The complete investor list: 17 names
- ·Watch Mirador Therapeutics: the Monday email on marks, rounds and moves
Mirador Therapeutics funding rounds
2 roundsWho backs Mirador Therapeutics
17+Mirador Therapeutics valuation
Mirador Therapeutics was valued at $1 billion at its early-stage round in Jan 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Mirador Therapeutics raised?
Mirador Therapeutics has raised $735 million in total; 2 of its rounds are on record. The largest on record was an $80 million later-stage round in Dec 2023; the most recent was a $333 million later-stage round in Feb 2024.
Mirador Therapeutics has filed 2 Form Ds with the SEC, most recently in Apr 2024 ($80 million sold to 3 investors).
Mirador Therapeutics investors
17 investors are on record for Mirador Therapeutics, including Alexandria Venture Investments, OrbiMed, ARCH Venture Partners and Venrock. By type, the record holds 4 hedge funds and 3 venture capital firms. The later-stage round in Feb 2024 drew 31 investors.
About Mirador Therapeutics
Developer of precision medicine technologies designed to address unmet needs in immune-mediated and inflammatory diseases. The company offers features such as a proprietary data analytics engine that harmonizes extensive patient molecular profiles, identifies novel therapeutic targets, and develops diagnostics, enabling researchers and healthcare providers to create targeted therapies based on individual genetics, ultimately improving treatment outcomes for patients suffering from chronic conditions.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2024
- Website
- miradortx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.